Frank A. Benedetto

Summary

Affiliation: Azienda Ospedaliera Bianchi-Melacrino-Morelli
Location: Reggio Calabria, Italia
URL: www.frankbenedetto.com
Summary:
clinical cardiology and rehabilitation
Publications:
eNOS and caveolin-1 gene polymorphisms interaction and intima media thickness: a proof of concept study in ESRD patients.
Testa A, Spoto B, Sanguedolce MC, Parlongo RM, Pisano A, Tripepi G, Benedetto FA, Mallamaci F, Zoccali C.
Am J Hypertens. 2012 Jan;25(1):103-8. doi: 10.1038/ajh.2011.178. Epub 2011 Oct 6.


Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients.
Testa A, Mallamaci F, Macrì R, Pisano A, Spoto B, Malatino LS, Stancanelli B, Tripepi G, Benedetto FA, Zoccali C.
J Hypertens. 2010 Aug;28(8):1745-51.

Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study.
Antonini-Canterin F, La Carrubba S, Gullace G, Zito C, Di Bello V, Di Salvo G, Benedetto F, Novo S, Pezzano A, Perticone F, Balbarini A, Carerj S; Research Group of the Italian Society of Cardiovascular Echography.
Angiology. 2010 Jul;61(5):443-8. Epub 2010 Mar 19
Detection of pulmonary congestion by chest ultrasound in dialysis patients.

Mallamaci F, Benedetto FA, Tripepi R, Rastelli S, Castellino P, Tripepi G, Picano E, Zoccali C.
JACC Cardiovasc Imaging. 2010 Jun;3(6):586-94.
Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients.
Testa A, Mallamaci F, Benedetto FA, Pisano A, Tripepi G, Malatino L, Thadhani R, Zoccali C.
J Bone Miner Res. 2010 Feb;25(2):313-9.
Soluble e-selectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients.

Stancanelli B, Malatino LS, Cataliotti A, Bellanuova I, Mallamaci F, Tripepi G, Benedetto FA, Leonardis D, Fatuzzo P, Rapisarda F, Zoccali C.
Nephron Clin Pract. 2010;114(1):c74-80. Epub 2009 Oct 23.
Carotid intima-media thickness in asymptomatic patients with arterial hypertension without clinical cardiovascular disease: relation with left ventricular geometry and mass and coexisting risk factors.
Di Bello V, Carerj S, Perticone F, Benedetto F, Palombo C, Talini E, Giannini D, La Carrubba S, Antonini-Canterin F, Di Salvo G, Bellieni G, Pezzano A, Romano MF, Balbarini A; Research Group of the Italian Society of CardioVascular Echocardiography (SIEC).
Angiology. 2009 Dec-2010 Jan;60(6):705-13

Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease.
Tripepi G, Mattace-Raso F, Mallamaci F, Benedetto FA, Witteman J, Malatino L, Zoccali C.
Hypertension. 2009 Oct;54(4):818-24. Epub 2009 Jul 27.
Vitamin D Receptor (VDR) Gene Polymorphism is Associated with Left Ventricular (LV) Mass and Predicts LVH Progression in End Stage Renal Disease (ESRD) Patients.
Testa A, Mallamaci F, Benedetto F, Pisano A, Tripepi G, Malatino L, Thadhani R, Zoccali C.
J Bone Miner Res. 2009 Jul 20. [Epub ahead of print]

Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.
Mallamaci F, Benedetto FA, Tripepi G, Cutrupi S, Pizzini P, Stancanelli B, Seminara G, Bonanno G, Rapisarda F, Fatuzzo P, Malatino LS, Zoccali C.
J Hypertens. 2008 Sep;26(9):1875-82.
Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD.

Benedetto FA, Tripepi G, Mallamaci F, Zoccali C.
J Am Soc Nephrol. 2008 Apr;19(4):757-63. Epub 2008 Jan 9.
Urotensin II and cardiomyopathy in end-stage renal disease.
Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Pizzini P, Cutrupi S, Malatino L.
Hypertension. 2008 Feb;51(2):326-33. Epub 2007 Dec 17.
An additive effect of endothelial nitric oxide synthase gene polymorphisms contributes to the severity of atherosclerosis in patients on dialysis.

Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, Boeger RH, Zoccali C.
Am J Hypertens. 2007 Jul;20(7):758-63.
Left atrial volume monitoring and cardiovascular risk in patients with end-stage renal disease: a prospective cohort study.
Tripepi G, Benedetto FA, Mallamaci F, Tripepi R, Malatino L, Zoccali C.
J Am Soc Nephrol. 2007 Apr;18(4):1316-22. Epub 2007 Mar 14.
Left atrial volume in end-stage renal disease: a prospective cohort study.

Tripepi G, Benedetto FA, Mallamaci F, Tripepi R, Malatino L, Zoccali C.
J Hypertens. 2006 Jun;24(6):1173-80.

Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study.
Zoccali C, Benedetto FA, Tripepi G, Mallamaci F, Rapisarda F, Seminara G, Bonanno G, Malatino LS.
J Am Soc Nephrol. 2006 May;17(5):1460-5. Epub 2006 Apr 5.

The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease.
Testa A, Benedetto FA, Spoto B, Pisano A, Tripepi G, Mallamaci F, Malatino LS, Zoccali C.
Nephrol Dial Transplant. 2006 Jul;21(7):1921-6. Epub 2006 Mar 22.

Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease.
Spoto B, Benedetto FA, Testa A, Tripepi G, Mallamaci F, Maas R, Boeger RH, Zoccali C, Parlongo RM, Pisano A.
Am J Hypertens. 2005 Dec;18(12 Pt 1):1549-55.
Cardiac consequences of hypertension in hemodialysis patients.

Zoccali C, Benedetto FA, Tripepi G, Mallamaci F.
Semin Dial. 2004 Jul-Aug;17(4):299-303. Review.

Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS.
Kidney Int. 2004 Apr;65(4):1492-8.
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS.
J Am Soc Nephrol. 2004 Apr;15(4):1029-37.
Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients.
Panuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C.
Am J Kidney Dis. 2004 Mar;43(3):479-84.

Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.
J Am Soc Nephrol. 2003 Oct;14(10):2611-7.

Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD).
Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Bonanno G, Seminara G, Fatuzzo P, Rapisarda F, Malatino LS.
Kidney Int. 2003 Aug;64(2):579-84.

Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.
J Hypertens. 2003 Jul;21(7):1355-62.

Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M.
Eur J Clin Invest. 2003 Jul;33(7):561-6.

Hepatocyte growth factor and left ventricular geometry in end-stage renal disease.
Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C.
Hypertension. 2003 Jan;41(1):88-92.

Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients.
Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS; Cardiovascular Risk Extended Evaluation in Dialysis Investigators.
Kidney Int. 2002 Nov;62(5):1884-90.

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease.
Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS; CREED investigators.
Hypertension. 2002 Jul;40(1):41-6.

Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients.
Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS.
Am J Kidney Dis. 2002 Jul;40(1):68-75.

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.
Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R; CREED Investigators.
Kidney Int. 2002 Jul;62(1):339-45.

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS.
Circulation. 2002 Mar 19;105(11):1354-9. Erratum in: Circulation 2002 May 7;105(18):2230. Cateliotti A [corrected to Cataliotti A].

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients.
Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A; CREED Investigators.
Kidney Int. 2002 Feb;61(2):609-14.

Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.
Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Böger R; CREED Investigators.
J Am Soc Nephrol. 2002 Feb;13(2):490-6.

Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.
J Am Soc Nephrol. 2002 Jan;13(1):134-41.

Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS; CREED Investigators.
J Am Soc Nephrol. 2001 Dec;12(12):2768-74.

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R.
Lancet. 2001 Dec 22-29;358(9299):2113-7

Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients.
Benedetto FA, Mallamaci F, Tripepi G, Zoccali C.
J Am Soc Nephrol. 2001 Nov;12(11):2458-64.

Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients.
Zoccali C, Mallamaci F, Asahia K, Benedetto FA, Tripepi G, Tripepi R, Nicocia G, Buemi M, Miyata T.
J Nephrol. 2001 Jul-Aug;14(4):293-8.

Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients.
Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C.
Nephrol Dial Transplant. 2001 Jul;16(7):1459-64.

Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.
Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators.
J Am Soc Nephrol. 2001 Jul;12(7):1508-15.

Diagnostic potential of cardiac natriuretic peptides in dialysis patients.
Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS; CREED Investigstors. The Cardiovascular Risk Extended Evaluation.
Kidney Int. 2001 Apr;59(4):1559-66.

Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V, Labate C, Tassone F.
J Hypertens. 2001 Feb;19(2):287-93.

Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA.
Nephrol Dial Transplant. 2001 Jan;16(1):70-7.
Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease.
Malatino LS, Mallamaci F, Benedetto FA, Bellanuova I, Cataliotti A, Tripepi G, Zoccali C.
Am J Kidney Dis. 2000 Nov;36(5):945-52.

Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Focà A, Paroni R, Malatino LS.
J Hypertens. 2000 Sep;18(9):1207-13.

Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators.
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cottini E, Giacone G, Malatino L.
J Hypertens. 1999 Dec;17(12 Pt 1):1751-8.

Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients.
Malatino LS, Benedetto FA, Mallamaci F, Tripepi G, Zoccali C, Parlongo S, Cutrupi S, Marino C, Panuccio V, Garozzo M, Candela V, Bellanuova I, Cataliotti A, Rapisarda F, Fatuzzo P, Bonanno G, Seminara G, Stancanelli B, Tassone F, Labate C.
J Nephrol. 1999 Jul-Aug;12(4):256-60.

Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients.
Zoccali C, Benedetto FA, Tripepi G, Cambareri F, Panuccio V, Candela V, Mallamaci F, Enia G, Labate C, Tassone F.
Kidney Int. 1998 Apr;53(4):1078-84.

Plasma endothelin-1 release in normal and varicose saphenous veins.
Mangiafico RA, Malatino LS, Santonocito M, Spada RS, Benedetto FA.
Angiology. 1997 Sep;48(9):769-74.

[Pseudothrombophlebitis due to an expansive popliteal cyst associated with Reiters syndrome].
Mangiafico RA, Santonocito M, Mandalà ML, Spada RS, Benedetto FA, Malatino LS.
Minerva Med. 1995 Sep;86(9):391-4. Review. Italian.

Publications

  1. ncbi request reprint Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients
    C Zoccali
    Centro di Fisiologia Clinica, Ospedali Morelli, Reggio Cal, Italy
    Kidney Int 53:1078-84. 1998
  2. ncbi request reprint Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
    Francesca Mallamaci
    CNR Centro Fisiologia Clinica e Divisione di Nefrologia, Ospedali Riuniti, Reggio Calabria, Italy
    Kidney Int 61:609-14. 2002
  3. ncbi request reprint Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease
    Carmine Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Circulation 105:1354-9. 2002
  4. ncbi request reprint Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients
    Francesca Mallamaci
    Divisione di Nefrologia e CNR, Centro di Fisiologia Clinica, Reggio Calabria, Italy
    Am J Kidney Dis 40:68-75. 2002
  5. ncbi request reprint Norepinephrine and concentric hypertrophy in patients with end-stage renal disease
    Carmine Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Hypertension 40:41-6. 2002
  6. ncbi request reprint Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients
    Francesca Mallamaci
    CNR Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Kidney Int 62:1884-90. 2002
  7. ncbi request reprint Hepatocyte growth factor and left ventricular geometry in end-stage renal disease
    Lorenzo S Malatino
    Clinica Medica L Condorelli, Department of Internal Medicine, University of Catania, Ospedale Vittorio Emanuele, Italy
    Hypertension 41:88-92. 2003
  8. ncbi request reprint Urotensin II and cardiomyopathy in end-stage renal disease
    Carmine Zoccali
    Consiglio Nationale delle Ricerche CNR Istituto di Biomedicina IBIM, Division of Nephrology, Dialysis and Transplantation, Reggio Calabria, Italy
    Hypertension 51:326-33. 2008
  9. ncbi request reprint Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients
    Alessandra Testa
    CNR IBIM, National Research Council, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    J Hypertens 28:1745-51. 2010
  10. ncbi request reprint Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease
    Carmine Zoccali
    CNR IBIM, Institute of Biomedicine, Epidemiology, and Pathophysiology of Renal Diseases and Hypertension, and Division of Nephrology, Morelli Hospital, Reggio Calabria, Italy
    J Am Soc Nephrol 14:2611-7. 2003

Detail Information

Publications46

  1. ncbi request reprint Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients
    C Zoccali
    Centro di Fisiologia Clinica, Ospedali Morelli, Reggio Cal, Italy
    Kidney Int 53:1078-84. 1998
    ..Nocturnal hypoxemia is associated with the "non-dipping" arterial pressure profile in dialysis patients. Disturbed respiratory control during the night may represent an important cardiovascular risk factor in dialysis patients...
  2. ncbi request reprint Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients
    Francesca Mallamaci
    CNR Centro Fisiologia Clinica e Divisione di Nefrologia, Ospedali Riuniti, Reggio Calabria, Italy
    Kidney Int 61:609-14. 2002
    ..We prospectively tested the prediction power of homocysteinemia for all-cause and cardiovascular outcomes in a cohort of 175 hemodialysis patients followed for 29 +/- 12 months...
  3. ncbi request reprint Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease
    Carmine Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Circulation 105:1354-9. 2002
    ....
  4. ncbi request reprint Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients
    Francesca Mallamaci
    Divisione di Nefrologia e CNR, Centro di Fisiologia Clinica, Reggio Calabria, Italy
    Am J Kidney Dis 40:68-75. 2002
    ..These data support the hypothesis that this marker can be usefully applied for risk stratification in clinically stable dialysis patients...
  5. ncbi request reprint Norepinephrine and concentric hypertrophy in patients with end-stage renal disease
    Carmine Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Hypertension 40:41-6. 2002
    ..003). Plasma NE is associated to concentric LVH in ESRD patients. These observations constitute a sound basis for testing the effect of anti-adrenergic drugs on left ventricle mass and on cardiovascular outcomes in patients with ESRD...
  6. ncbi request reprint Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients
    Francesca Mallamaci
    CNR Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    Kidney Int 62:1884-90. 2002
    ..We tested the diagnostic value of cTnT for left ventricular hypertrophy (LVH) and LV systolic dysfunction in a large group of clinically stable hemodialysis patients without heart failure...
  7. ncbi request reprint Hepatocyte growth factor and left ventricular geometry in end-stage renal disease
    Lorenzo S Malatino
    Clinica Medica L Condorelli, Department of Internal Medicine, University of Catania, Ospedale Vittorio Emanuele, Italy
    Hypertension 41:88-92. 2003
    ....
  8. ncbi request reprint Urotensin II and cardiomyopathy in end-stage renal disease
    Carmine Zoccali
    Consiglio Nationale delle Ricerche CNR Istituto di Biomedicina IBIM, Division of Nephrology, Dialysis and Transplantation, Reggio Calabria, Italy
    Hypertension 51:326-33. 2008
    ..Additional mechanistic insights may be needed before launching long-term clinical trials with UTN antagonists in patients with end-stage renal disease...
  9. ncbi request reprint Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients
    Alessandra Testa
    CNR IBIM, National Research Council, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    J Hypertens 28:1745-51. 2010
    ..Plasma levels of NPY are increased in patients with end-stage renal disease (ESRD) and are independently related to left ventricular hypertrophy (LVH) and incident cardiovascular events in these patients...
  10. ncbi request reprint Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease
    Carmine Zoccali
    CNR IBIM, Institute of Biomedicine, Epidemiology, and Pathophysiology of Renal Diseases and Hypertension, and Division of Nephrology, Morelli Hospital, Reggio Calabria, Italy
    J Am Soc Nephrol 14:2611-7. 2003
    ..Controlled trials are needed to establish whether interference with the sympathetic system, NPY, or both may reduce the high CV morbidity and mortality of dialysis patients...
  11. ncbi request reprint Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients
    Vincenzo Panuccio
    National Research Council, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    Am J Kidney Dis 43:479-84. 2004
    ..The prognostic value of cardiac valve calcifications and their relationship with left ventricular hypertrophy and background cardiovascular risk in hemodialysis patients is still unknown...
  12. ncbi request reprint Left atrial volume in end-stage renal disease: a prospective cohort study
    Giovanni Tripepi
    CNR IBIM, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension and Division of Nephrology, Reggio Calabria, Italy
    J Hypertens 24:1173-80. 2006
    ..End-stage renal disease (ESRD) is a high-risk condition and left ventricular hypertrophy (LVH) is the strongest risk factor in this population...
  13. ncbi request reprint Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients
    Francesca Mallamaci
    CNR IBIM, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Disease and Hypertension, Reggio Calabria, Italy
    J Hypertens 26:1875-82. 2008
    ..We investigated the relationship between vascular endothelial growth factor, left ventricular function (by midwall fractional shortening) and mortality in a prospective cohort study in 228 hemodialysis patients...
  14. doi request reprint Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease
    Giovanni Tripepi
    CNR IBIM, Istituto di Biomedicina, Epidemiologia Clinica e Fisiopatologia, delle Malattie Renali e dell Ipertensione Arteriosa, c o EUROLINE di Ascrizzi Vincenzo, via Vallone Petrara 55 57, Reggio Calabria, Italy
    Hypertension 54:818-24. 2009
    ....
  15. ncbi request reprint Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease
    Carmine Zoccali
    National Research Council Center of Clinical Physiology, Reggio Calabria, Italy
    J Am Soc Nephrol 13:134-41. 2002
    ..Furthermore, ADPN is related to several metabolic risk factors in a manner consistent with the hypothesis that this protein acts as a protective factor for the cardiovascular system...
  16. ncbi request reprint Detection of pulmonary congestion by chest ultrasound in dialysis patients
    Francesca Mallamaci
    Nephrology and Renal Transplantation Unit Ospedali Riuniti, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    JACC Cardiovasc Imaging 3:586-94. 2010
    ..This study sought to investigate clinical and echocardiographic correlates of the lung comets score...
  17. doi request reprint Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients
    Alessandra Testa
    CNR IBIM, Research Unit of Clinical Epidemiology and Physiopathology of Renal Disease and Hypertension, Reggio Calabria, Italy
    J Bone Miner Res 25:313-9. 2010
    ..These cross-sectional and longitudinal observations coherently support the hypothesis that altered vitamin D signaling is implicated in LVH in ESRD patients...
  18. ncbi request reprint Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients
    C Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Ospedali Riuniti, Reggio Calabria, Italy
    Nephrol Dial Transplant 16:70-7. 2001
    ..It remains to be seen whether the link between nocturnal hypoxaemia and autonomic dysfunction is a causal one...
  19. doi request reprint Soluble e-selectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients
    Benedetta Stancanelli
    Division of Internal Medicine, Hypertension and Cardio Renal Diseases Centre, Department of Internal Medicine and Systemic Diseases, University of Catania, c o Ospedale Civile, Ragusa, Italy
    Nephron Clin Pract 114:c74-80. 2010
    ..In end-stage renal disease (ESRD), the relationship of E-selectin with left ventricular function has been so far neglected...
  20. ncbi request reprint Diagnostic potential of cardiac natriuretic peptides in dialysis patients
    F Mallamaci
    CNR Centro Fisiologia Clinica e Divisione di Nefrologia, Ospedali Riuniti, Reggio Calabria, Italy
    Kidney Int 59:1559-66. 2001
    ..CONCLUSIONS: Measuring the plasma concentration of cardiac natriuretic hormones, particularly BNP, may be useful for the identification of dialysis patients with LVH or for excluding systolic dysfunction...
  21. ncbi request reprint Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients
    C Zoccali
    Centro di Fisiologia Clinica del CNR e Divisione di Nefrologia, Via Sbarre Inferiori 39, 89100, Reggio Calabria, Italy
    J Am Soc Nephrol 12:1508-15. 2001
    ..The measurement of the plasma concentration of BNP and ANP may be useful for risk stratification in these patients...
  22. ncbi request reprint Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients
    C Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    J Nephrol 14:293-8. 2001
    ..To assess the relationship between advanced glycation end products (AGE) and cardiovascular damage in end-stage renal diseases...
  23. doi request reprint Carotid intima-media thickness in asymptomatic patients with arterial hypertension without clinical cardiovascular disease: relation with left ventricular geometry and mass and coexisting risk factors
    Vitantonio Di Bello
    Cardiac Thoracic and Vascular Department, University of Pisa, Pisa, Italy
    Angiology 60:705-13. 2009
    ..Altered patterns of LV geometry and carotid structural changes occur in many patients with essential hypertension. LVH or carotid remodeling are greater in elderly, in patients with higher systolic BP and with associated CV risk factors...
  24. ncbi request reprint The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease
    Alessandra Testa
    CNR IBIM, National Research Council Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    Nephrol Dial Transplant 21:1921-6. 2006
    ..The frequency of this polymorphism was also measured in a population sample of the same geographical area...
  25. doi request reprint Association between carotid atherosclerosis and metabolic syndrome: results from the ISMIR study
    Francesco Antonini-Canterin
    Preventive Cardiology, ARC, S Maria degli Angeli Hospital, Pordenone, Italy
    Angiology 61:443-8. 2010
    ..Our study confirms the association between MetS and carotid atherosclerosis. In MetS, a significant correlation between carotid IMT and triglycerides and fibrinogen levels was found...
  26. pmc Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD
    Francesco Antonio Benedetto
    CNR IBIM, Istituto di Biomedicina, Unità Operativa di Nefrologia Dialisi e Trapianto Renale, Epidemiologia Clinica e Fisiopatologia, delle Malattie Renali e dell Ipertensione Arteriosa, c o EUROLINE di Ascrizzi Vincenzo, Reggio Calabria, Italy
    J Am Soc Nephrol 19:757-63. 2008
    ....
  27. ncbi request reprint Left atrial volume monitoring and cardiovascular risk in patients with end-stage renal disease: a prospective cohort study
    Giovanni Tripepi
    Consiglio Nazionale Ricerche Istituto Biomedicina, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension and Division of Nephrology, University of Catania, Catania, Italy
    J Am Soc Nephrol 18:1316-22. 2007
    ..Monitoring LA size by echocardiography is useful for monitoring CV risk in patients with ESRD...
  28. ncbi request reprint Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients
    C Zoccali
    CNR, Centre of Clinical Physiology and Division of Nephrology Ospedali Riuniti, Reggio Cal, Italy
    J Hypertens 19:287-93. 2001
    ..In this study we have tested the hypothesis that this disturbance is associated with left ventricular hypertrophy (LVH) in dialysis patients...
  29. ncbi request reprint An additive effect of endothelial nitric oxide synthase gene polymorphisms contributes to the severity of atherosclerosis in patients on dialysis
    Belinda Spoto
    CNR IBIM, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension and Division of Nephrology, Reggio Calabria, Italy
    Am J Hypertens 20:758-63. 2007
    ..Reduced synthesis of nitric oxide (NO) is considered a major proatherogenic mechanism in patients with end-stage renal disease (ESRD), but genetic factors impinging on this mechanism have been little studied in this population...
  30. ncbi request reprint Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study
    Carmine Zoccali
    National Research Council Institute of Biomedicine, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension of Reggio Calabria, Reggio Calabria, Italy
    J Am Soc Nephrol 17:1460-5. 2006
    ..02) than in those who had a decrease in mwFS. Changes in mwFS have an independent prognostic value for CV events, and periodic echocardiographic studies of systolic function are useful for monitoring asymptomatic dialysis patients...
  31. ncbi request reprint Atherosclerosis and the Glu298Asp polymorphism of the eNOS gene in white patients with end-stage renal disease
    Belinda Spoto
    CNR IBIM, National Research Council Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio, Calabria, Italy
    Am J Hypertens 18:1549-55. 2005
    ....
  32. ncbi request reprint Cardiac consequences of hypertension in hemodialysis patients
    Carmine Zoccali
    Istituto di Biomedicina Epidemiologia Clinica e Fisiopatologia delle malattie Renali e dell Ipertensione Arteriosa e Unita Operativa di Nefrologia, Dialisi e Trapianto Renale, Ospedali Riuniti, Reggio Calabria, Italy
    Semin Dial 17:299-303. 2004
    ..Despite the lack of evidence from randomized controlled trials, it appears reasonable that interventions aimed at curbing the high CV mortality of ESRD should be targeted to both hypertension and LVH...
  33. ncbi request reprint Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators
    C Zoccali
    CNR Center of Clinical Physiology and Division of Nephrology, Ospedali Riuniti, Reggio Calabria, Italy
    J Hypertens 17:1751-8. 1999
    ..However, whether 24-h monitoring is a better predictor of LVH than clinic blood pressure and routine pre-dialysis measurements in these patients is still undefined...
  34. ncbi request reprint Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients
    C Zoccali
    CNR Centro Fisiologia Clinica e Divisione di Nefrologia, Ospedali Riuniti, Reggio Cal, Italy
    J Hypertens 18:1207-13. 2000
    ..To investigate the relationship between inflammatory processes and atherosclerosis in uraemic patients on chronic dialysis...
  35. ncbi request reprint Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients
    G Enia
    Centro di Fisiologia Clinica del CNR e Divisione di Nefrologia, Reggio Calabria, Italy
    Nephrol Dial Transplant 16:1459-64. 2001
    ..This finding is associated with evidence of more pronounced volume expansion, hypertension, and hypoalbuminaemia. Volume and pressure load along with factors associated with hypoalbuminaemia may aggravate LVH in uraemic patients on CAPD...
  36. ncbi request reprint Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients
    F A Benedetto
    CNR, Centre of Clinical Physiology and Division of Nephrology, Reggio Calabria, Italy
    J Am Soc Nephrol 12:2458-64. 2001
    ..IMT in dialysis patients is associated with LV concentric hypertrophy and is an independent predictor of cardiovascular death. IMT may be usefully applied for risk stratification in the dialysis population...
  37. ncbi request reprint Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis
    C Zoccali
    Centre of Clinical Physiology and Division of Nephrology, Morelli Hospital, Reggio Cal, Italy
    J Am Soc Nephrol 12:2768-74. 2001
    ..The indexing of LVM by height(2.7) provides more powerful prediction of mortality and cardiovascular outcomes than the BSA-based method, and the use of this index appears to be appropriate in patients undergoing dialysis...
  38. ncbi request reprint Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
    C Zoccali
    CNR Centre of Clinical Physiology and Renal Unit, Reggio, Italy
    Lancet 358:2113-7. 2001
    ..These findings lend support to the hypothesis that accumulation of ADMA is an important risk factor for cardiovascular disease in chronic renal failure...
  39. ncbi request reprint Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease
    Carmine Zoccali
    CNR Centre of Clinical Physiology and Renal Unit, Morelli Hospital, Reggio, Calabria, Italy
    J Am Soc Nephrol 13:490-6. 2002
    ..These data support the hypothesis that accumulation of this endogenous inhibitor of NO synthase is an important risk factor for cardiovascular disease in chronic renal failure and suggest a possible link between ADMA and inflammation...
  40. ncbi request reprint Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients
    Carmine Zoccali
    CNR, Division of Nephrology, Centre of Clinical Physiology and Renal Unit, Via Sbarre Inferiori 39, 89131 Reggio Calabria, Italy
    Kidney Int 62:339-45. 2002
    ..The endogenous inhibitor of nitric oxide (NO), asymmetric dimethylarginine (ADMA), is a strong predictor of adverse cardiovascular outcomes in patients with end-stage renal disease (ESRD)...
  41. ncbi request reprint Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure
    C Zoccali
    Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, c o Ospedali Riuniti Bianchi Melacrino Morelli Via Vallone Petrara, 89124 Reggio Calabria, Italy
    Eur J Clin Invest 33:561-6. 2003
    ..We investigated the relationship between fibrinogen and echocardiographic measurements of left ventricular (LV) geometry and LV function in a group of 192 patients with end stage renal disease (ESRD)...
  42. ncbi request reprint Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease
    Carmine Zoccali
    CNR, Institute of Biomedicine, Epidemiology and Pathophysiology of Renal Diseases and Hypertension and Division of Nephrology, Morelli Hospital, Reggio Calabria, Italy
    J Hypertens 21:1355-62. 2003
    ....
  43. ncbi request reprint Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD)
    Carmine Zoccali
    National Research Council CNR, Institute of Biomedicine, Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    Kidney Int 64:579-84. 2003
    ..Cross-sectional and retrospective studies suggest that Chlamydia pneumoniae infection may contribute importantly to the high cardiovascular risk of patients with end-stage renal disease (ESRD)...
  44. ncbi request reprint Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients
    Carmine Zoccali
    CNR IBIM National Research Council, Institute of Biomedicine, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Ospedali Riuniti Via Vallone Petrara, 89124 Reggio Calabria, Italy
    J Am Soc Nephrol 15:1029-37. 2004
    ..Risk stratification by simple systolic function parameters may prove useful in secondary prevention strategies in these patients...
  45. ncbi request reprint Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression
    Carmine Zoccali
    Institute of Biomedicine Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy
    Kidney Int 65:1492-8. 2004
    ..Whether changes in left ventricular mass (LVM) in clinical practice predict survival and cardiovascular events in these patients is still unknown...
  46. ncbi request reprint Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients
    L S Malatino
    Istituto di Clinica Medica L Condorelli, Reggio Calabria, Italy
    J Nephrol 12:256-60. 1999
    ..To investigate the relationship between carotid atherosclerosis and some major cardiovascular risk factors in uremic patients on chronic dialysis...